The Conversation (0)
April 28, 2025
INN Article Notification
29 August 2025
Appendix 4E and Preliminary Final Report
Radiopharm Theranostics (RAD:AU) has announced Appendix 4E and Preliminary Final ReportDownload the PDF here. Keep Reading...
29 July 2025
Quarterly Activities/Appendix 4C Cash Flow Report
Radiopharm Theranostics (RAD:AU) has announced Quarterly Activities/Appendix 4C Cash Flow ReportDownload the PDF here. Keep Reading...
27 July 2025
RAD receives IND approval from US FDA for Betabart (RV-01)
Radiopharm Theranostics (RAD:AU) has announced RAD receives IND approval from US FDA for Betabart (RV-01)Download the PDF here. Keep Reading...
10 June 2025
RAD Granted US FDA Fast Track for RAD101 Metastases Imaging
Radiopharm Theranostics (RAD:AU) has announced RAD Granted US FDA Fast Track for RAD101 Metastases ImagingDownload the PDF here. Keep Reading...
03 June 2025
RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202
Radiopharm Theranostics (RAD:AU) has announced RAD Doses 1st Patient in Therapeutic Trial of 177Lu-RAD202Download the PDF here. Keep Reading...
07 May
Lexaria Bioscience Releases Second Episode of Investor Video Series
CEO Rich Christopher Discusses Recently Announced Material Transfer Agreement Extension and 2026 Research Priorities KELOWNA, BC / ACCESS Newswire / May 7, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, today... Keep Reading...
07 May
BriaCell Adds NYU Langone Health's Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study
briacell therapeutics corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT) ("BriaCell" or the "Company"), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care is pleased to announce the addition of NYU Langone Health's Laura and Isaac Perlmutter Cancer Center, a... Keep Reading...
06 May
BriaCell Receives FDA Clearance to Initiate Bria-BRES+ Clinical Study in Breast Cancer
FDA clearance of Investigational New Drug (IND) application opens path to commence Phase 1/2a clinical study for Bria-BRES+ in metastatic breast cancerBria-BRES+ is BriaCell's next generation personalized immunotherapy for breast cancer, and features additional immune activating components... Keep Reading...
05 May
Lexaria Updates Progress on Human Study #7
KELOWNA, BC / ACCESS Newswire / May 5, 2026 / Lexaria Bioscience Corp. (NASDAQ:LEXX) ("Lexaria" or the "Company"), a global innovator in oral drug delivery platforms, provides this update on Human Pilot Study #7 (GLP-1-H26-7) that will evaluate two oral DehydraTECH-semaglutide ("DHT-sema")... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00